Lifeboat Foundation

Airborne pollutants including viruses, mould, bacteria, dust, and harmful gasses cause millions of deaths annually. Solutions are available.

Bright indoor lighting during daytime.

According to a new study published in Diabetologia, Insulin-resistant volunteers’ postprandial substrate processing, energy expenditure, and thermoregulation are all affected by the indoor light environment in a time-dependent manner. Further Optimization of indoor lighting to a brighter during daytime hours and dimmer in the evening may provide cardiometabolic benefits.

Artificial light is available 24 hours a day in today’s civilization, and most individuals are exposed to electrical light and light-emitting screens during the dark part of the natural light/dark cycle. Suboptimal lighting has been linked to negative metabolic impacts, and changing indoor lighting to more closely mirror the natural light/dark cycle has the potential to improve metabolic health.

Continue reading “Bright indoor light during daytime may lower blood sugar, improve energy expenditure” »

Measuring Human Biology in Action, To Cure, Prevent Or Manage All Diseases — Dr. Stephani Otte, Ph.D., Science Program Officer, Imaging, Chan Zuckerberg Initiative.

Dr. Stephani Otte, Ph.D is Science Program Officer, Imaging, at the Chan Zuckerberg Initiative (https://chanzuckerberg.com/), who leads the organization’s Imaging program and is focused on the creation, dissemination, optimization, and standardization of transformative imaging technologies.

Continue reading “Dr. Stephani Otte, Ph.D. — Chan Zuckerberg Initiative — Measuring Human Biology in Action” »

The AI revolution is here. Machine learning (ML) and artificial intelligence are used in virtually every industry today to revolutionize everything from reducing food waste to achieving better health outcomes. In all, IDC forecasts that global enterprise spending on AI will eclipse $204 billion by 2025.

Unfortunately, investments in needed infrastructure may not be keeping pace. Many enterprises are shipping AI blind or relying on outdated model monitoring approaches to catch issues with models in production.

In order to understand the scope of the problem and provide insights on potential solutions, Arize AI recently conducted a survey of 945 data scientists, engineers, executives, and others in the industry. The results speak to a distinct need for better tools to quickly visualize where and why problems are emerging and enable faster root cause analysis when models fail.

David M’zee was 22 when an injury damaged his spine, leaving him paralysed 12 years ago.

In 2017, an electrical implant to his spine enabled him to stand and walk slowly by boosting the nerve signals to his legs.

Continue reading “Electrical spinal implant helps paralysed man have child — BBC News” »

By Helen O’Shea

On a windy, bright day in Lemoore, California another 250 megawatts of clean power was added to California’s energy mix with the dedication of the Aquamarine Solar Project. There are many new solar projects coming online across the country these days, but the Aquamarine project is notable for its innovative development model — it’s part of a 20,000-acre master-planned solar park on fallowed and salt-contaminated agricultural lands in the Westlands Water District in California’s Central Valley.

Disturbed lands farmed for years with no residual habitat value are the perfect place to locate utility-scale solar projects. In 2016 these lands, among many others, were identified as suitable for development by a diverse group of stakeholders through the San Joaquin Valley Least Conflict Solar Planning exercise.

Japanese architecture studios Unemori Architects and Teco Architects have turned a commercial building in Kitakami, Japan, into a health and childcare support centre, adding a new facade as well as undulating floors and ceilings.

On this land taken from Indigenous Peoples, a new nation was eventually born, largely built by those whose ancestries traced back to the Old World via immigration and slavery.

As the country grew, inventions like the telephone, airplane, and Internet helped usher in today’s interconnected world. But the inexorable march of technological progress has come at great cost to the health of the planet, particularly because of global dependence on fossil fuels. The United Nations declared in 2017 that a Decade of Ocean Science for Sustainable Development would be held from 2021 to 2030. This Ocean Decade calls for a worldwide effort to reverse the oceans’ degradation.

The dawn of this decade, 2020, also marked the 400th anniversary of the Mayflower’s journey. Plymouth 400, a cultural nonprofit, has been working for more than a decade to commemorate the anniversary in ways that honor all aspects of this history, said spokesperson Brian Logan. Events began in 2020, but one of the most innovative launches is still waiting in the wings—a newfangled nautical craft, the Mayflower Autonomous Ship, or MAS.

Phase I trial aims to build on response seen in proof-of-concept trial.

NEW YORK AND CAMBRIDGE, MASS. — JANUARY 27, 2022 — IAVI and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C. The Phase I trial, IAVI G002, is designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and guide their early maturation toward broadly neutralizing antibody (bnAb) development. The induction of bnAbs is widely considered to be a goal of HIV vaccination, and this is the first step in that process. The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna’s mRNA technology.

IAVI and Moderna and do not necessarily reflect the views of USAID or the United States government.

Continue reading “IAVI and Moderna launch trial of HIV vaccine antigens delivered through mRNA technology” »